Vor Biopharma Inc.VOR stock score: 43/100
$18.52 · +3.87% · Scored Nov 19, 2026
- Technical
- 44
- Fundamental
- 43
- News
- 51
The reading
Vor Biopharma (VOR) scores 43 out of 100, which reads weak, higher than 30% of Healthcare stocks and 28% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 43, technicals 44.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Free Cash Flow Yield at 0 weighs the most against it.
On the daily chart, trend-following indicators average 38 and contrarian oscillators 61.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 35 to 46, and it ends the period where it started.
About Vor Biopharma
Vor Biopharma (VOR), which operates as Vor Bio, is a clinical-stage biotechnology company developing treatments for autoimmune diseases. Its lead product candidate is telitacicept, a fusion protein that blocks two proteins, BLyS and APRIL, which help drive the B cells and plasma cells behind many autoimmune conditions. Vor licensed global rights to telitacicept outside Greater China from RemeGen, which developed the drug and markets it in China for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. Vor is running a global late-stage trial of telitacicept in generalized myasthenia gravis and is exploring other indications. It has also licensed RC298, an early-stage, longer-acting BLyS and APRIL candidate, from RemeGen. The company has no product revenue and funds its research through stock sales, and it owes RemeGen milestone payments and royalties if its drugs succeed.
Vor competes with companies developing treatments for myasthenia gravis and other autoimmune diseases, including argenx, UCB and Johnson & Johnson, as well as Vera Therapeutics, which is developing a drug that targets the same pathway. Its edge rests on a late-stage asset that already has clinical and commercial experience in China and a dual-targeting approach. Investors who follow VOR stock tend to watch results from the global trial of telitacicept and the timing of regulatory filings. Cash runway is closely followed. Plans for additional indications, partnership terms with RemeGen and share dilution are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward VOR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
43Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
Net income growth from the prior fiscal year to the latest.
21 weighted scorers; 18 had no data today and are left out rather than counted as zero.
Technical · daily
42Pulling it up
Where the close sits against its 200-day EMA.
The price change over the last 52 weeks.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Where the close sits against its 100-day SMA.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 53 | 1 |
| Daily | 42 | 3 |
| Weekly | 37 | 2 |
| Monthly | 48 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 43 |
| Nov 18, 2026 | 42 |
| Nov 17, 2026 | 42 |
| Nov 16, 2026 | 43 |
| Nov 15, 2026 | 44 |
| Nov 14, 2026 | 44 |
| Nov 13, 2026 | 43 |
| Nov 12, 2026 | 41 |
| Nov 11, 2026 | 45 |
| Nov 10, 2026 | 41 |
| Nov 8, 2026 | 41 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 41 |
| Nov 5, 2026 | 38 |
| Nov 4, 2026 | 44 |
| Nov 3, 2026 | 43 |
| Nov 2, 2026 | 40 |
| Nov 1, 2026 | 41 |
| Oct 30, 2026 | 41 |
| Oct 29, 2026 | 45 |
| Oct 28, 2026 | 44 |
| Oct 27, 2026 | 41 |
| Oct 26, 2026 | 36 |
| Oct 25, 2026 | 36 |
| Oct 24, 2026 | 36 |
| Oct 23, 2026 | 36 |
| Oct 22, 2026 | 38 |
| Oct 21, 2026 | 39 |
| Oct 20, 2026 | 38 |
| Oct 19, 2026 | 36 |
| Oct 18, 2026 | 36 |
| Oct 17, 2026 | 36 |
| Oct 16, 2026 | 36 |
| Oct 15, 2026 | 39 |
| Oct 14, 2026 | 37 |
| Oct 13, 2026 | 38 |
| Oct 12, 2026 | 41 |
| Oct 11, 2026 | 40 |
| Oct 10, 2026 | 40 |
| Oct 9, 2026 | 40 |
| Oct 8, 2026 | 39 |
| Oct 7, 2026 | 37 |
| Oct 6, 2026 | 36 |
| Oct 5, 2026 | 37 |
| Oct 4, 2026 | 37 |
| Oct 3, 2026 | 37 |
| Oct 2, 2026 | 37 |
| Oct 1, 2026 | 35 |
| Sep 30, 2026 | 37 |
| Sep 29, 2026 | 36 |
| Sep 28, 2026 | 35 |
| Sep 27, 2026 | 36 |
| Sep 26, 2026 | 36 |
| Sep 25, 2026 | 36 |
| Sep 24, 2026 | 36 |
| Sep 23, 2026 | 39 |
| Sep 22, 2026 | 43 |
| Sep 21, 2026 | 43 |
| Sep 20, 2026 | 40 |
| Sep 19, 2026 | 40 |
| Sep 18, 2026 | 42 |
| Sep 17, 2026 | 41 |
| Sep 16, 2026 | 40 |
| Sep 15, 2026 | 42 |
| Sep 14, 2026 | 43 |
| Sep 13, 2026 | 43 |
| Sep 12, 2026 | 43 |
| Sep 11, 2026 | 42 |
| Sep 10, 2026 | 41 |
| Sep 9, 2026 | 43 |
| Sep 8, 2026 | 46 |
| Sep 7, 2026 | 45 |
| Sep 6, 2026 | 46 |
| Sep 5, 2026 | 45 |
| Sep 4, 2026 | 45 |
| Sep 3, 2026 | 45 |
| Sep 2, 2026 | 45 |
| Sep 1, 2026 | 43 |
| Aug 31, 2026 | 41 |
| Aug 30, 2026 | 42 |
| Aug 29, 2026 | 42 |
| Aug 28, 2026 | 42 |
| Aug 27, 2026 | 44 |
| Aug 26, 2026 | 44 |
| Aug 25, 2026 | 45 |
| Aug 24, 2026 | 43 |
| Aug 23, 2026 | 43 |
Key facts
- Market cap
- $1.1B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.83
- Risk grade (1–10)
- 10
- Next earnings
- Oct 30, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| GPCR Structure Therapeutics | $1.2B | 29 |
| AAPG Ascentage Pharma Group Internat | $1.2B | 45 |
| SVRA Savara | $1.1B | 38 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| INBX Inhibrx Biosciences | $1.1B | 38 |
| ANRO Alto Neuroscience | $1.1B | 36 |
Questions
What is VOR's stock rating today?
VOR scores 43/100 (Weak) as of Nov 19, 2026: technical 44, fundamental 43, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does Vor Biopharma do?
Vor Biopharma (VOR), which operates as Vor Bio, is a clinical-stage biotechnology company developing treatments for autoimmune diseases. Its lead product candidate is telitacicept, a fusion protein that blocks two proteins, BLyS and APRIL, which help drive the B cells and plasma cells behind many autoimmune conditions.
Is VOR stock a buy?
The score is not a buy or sell recommendation. A 43 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the VOR score calculated?
83 weighted scorers feed it today: 21 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/vor/"><img src="https://stocksscores.com/stocks/vor/badge.svg" alt="VOR stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/vor/)